SERPINE1 and empyema: Since the level of the molecular target, PAI-1, in chronic (7 d) empyema in rabbits was significantly lower than that in the acute stage (Figure 1, panel (c), A), a dose at half of the MED determined in the acute model [41,42] was chosen as the starting dose for treatment of chronic empyema in this rabbit model.